Camrelizumab
- Generic Name
- Camrelizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1798286-48-2
- Unique Ingredient Identifier
- 73096E137E
- Background
Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
- Indication
⑴用于至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤患者的治疗。
⑵用于霍奇金淋巴瘤（三线）、肝细胞癌（二线）、非鳞状非小细胞肺癌（一线联合）、食管鳞癌（二线）。
⑶用于既往接受过二线及以上化疗后疾病进展或不可耐受的晚期鼻咽癌患者的治疗。
⑷联合顺铂和吉西他滨用于局部复发或转移性鼻咽癌患者的一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Camrelizumab Combined With Apatinib for Recurrent Resistant GTN
- Conditions
- Interventions
- First Posted Date
- 2019-08-06
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04047017
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma
- Conditions
- Interventions
- First Posted Date
- 2019-08-05
- Last Posted Date
- 2020-05-19
- Lead Sponsor
- Peking University People's Hospital
- Registration Number
- NCT04044378
- Locations
- 🇨🇳
Lu Xie, Beijing, Beijing, China
SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma
- First Posted Date
- 2019-07-10
- Last Posted Date
- 2019-07-11
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04014101
- Locations
- 🇨🇳
Zhongshan Hospital, Shanghai, Shanghai, China
Camrelizumab(SHR-1210) Combined With Apatinib in the Treatment of Advanced Metastatic Colorectal Cancer
- First Posted Date
- 2019-04-11
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 50
- Registration Number
- NCT03912857
- Locations
- 🇨🇳
Cancer center of Sun Yat-sen University, Guangzhou, Guangdong, China
A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors
- First Posted Date
- 2019-03-12
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 8
- Registration Number
- NCT03871855
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-01-25
- Last Posted Date
- 2023-04-11
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 45
- Registration Number
- NCT03816553
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳The First affiliated Hospital of Sun Yat-sen University, Guanzhou, Guangdong, China
🇨🇳Guangzhou Panyu Central Hospital, Guangzhou, Guangdong, China
A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCC
- First Posted Date
- 2019-01-25
- Last Posted Date
- 2019-01-25
- Target Recruit Count
- 725
- Registration Number
- NCT03817658
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
A Study to Evaluate SHR-1210 in Combination With Capecitabine + Oxaliplatin Sequenced by SHR-1210 + Apatinib as First-line Therapy in Treatment of Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-01-23
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 885
- Registration Number
- NCT03813784
- Locations
- 🇨🇳
Beijing Cancer Hospital, Peking University, Beijing, Beijing, China
Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer
- First Posted Date
- 2018-12-17
- Last Posted Date
- 2019-01-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 230
- Registration Number
- NCT03777124
A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC
- Conditions
- Interventions
- First Posted Date
- 2018-12-05
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 543
- Registration Number
- NCT03764293
- Locations
- 🇺🇸
Renovatio Clinical, The Woodlands, Texas, United States
🇨🇳The 940th Hospital of the joint logistic support force of People's Liberation Army, Lanzhou, Gansu, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.